Clinical Trial

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MBX 4291 in Adult Participants With Obesity

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
The purpose of this study is to evaluate the safety and tolerability of single and multiple subcutaneous (SC) doses of MBX 4291 in adults with obesity.
Protocol Amendment History 4 changes
notable Enrollment increased: 64 -> 124 participants 2026-04-29
minor Trial arms changed: 3 -> 4 2026-04-29
notable Primary completion pushed: 2026-05-30 -> 2026-10-30 2026-04-29
minor Completion pushed: 2026-05-30 -> 2026-10-30 2026-04-29
Trial Details
NCT Number NCT07142707
Lead Sponsor MBX Biosciences
Conditions Obesity
Enrollment 124 participants
Start Date 2025-09-03
Primary Completion 2026-10-30 (estimated)
Study Completion 2026-10-30 (estimated)
Updated on ClinicalTrials.gov 2026-06-09